The chief medical officer at Acumen Pharmaceuticals discussed the benefits of using the blood-based p-tau 217 biomarker to improve screening accuracy and reduce patient burden in AD. [WATCH TIME: 5 minutes]
Eric Siemers, MD
Advertisement
Articles by Eric Siemers, MD
Advertisement
Latest Updated Articles
Advances in Alzheimer Disease Screening and Antibody Therapy at AAIC 2025: Eric Siemers, MDPublished: August 13th 2025 | Updated:
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
CAVS-MS Analysis Adds Further Validation to Utility of Paramagnetic Rim Lesions in MS Diagnosis
2
Highlighting Research Progress and Upcoming NMOSD Clinical Trial: Sumaira Ahmed
3
International Panel Revises NMOSD Diagnostic Criteria Based on Evidence-Based Consensus
4
High Dose Nusinersen, Apitegromab Receive CRLs, Tolebrutinib PDUFA Pushed Back
5
